Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been given an average rating of “Moderate Buy” by the six research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.25.

A number of analysts recently weighed in on the stock. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Wall Street Zen lowered shares of Xeris Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. HC Wainwright reissued a “buy” rating and set a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum upped their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th. Finally, Leerink Partners raised their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th.

Insider Activity

In other news, insider Beth Hecht sold 40,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. The trade was a 2.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 6.47% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Rhumbline Advisers raised its holdings in shares of Xeris Biopharma by 6.3% in the first quarter. Rhumbline Advisers now owns 192,281 shares of the company’s stock valued at $1,056,000 after purchasing an additional 11,317 shares during the last quarter. Strs Ohio bought a new position in Xeris Biopharma in the first quarter valued at $334,000. Acadian Asset Management LLC acquired a new stake in Xeris Biopharma in the 1st quarter valued at $96,000. Caxton Associates LLP acquired a new stake in Xeris Biopharma in the 1st quarter valued at $170,000. Finally, Fred Alger Management LLC bought a new stake in Xeris Biopharma during the 1st quarter worth about $736,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $4.58 on Tuesday. The firm has a fifty day moving average of $4.56 and a two-hundred day moving average of $4.08. The stock has a market capitalization of $716.24 million, a price-to-earnings ratio of -10.18 and a beta of 0.71. Xeris Biopharma has a 52 week low of $2.03 and a 52 week high of $6.07.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. As a group, research analysts forecast that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.